Table 1. Clinical data of 110 patients with laryngeal squamous cell carcinoma (LSCC).
| Count | % of total | Mean | ||
|---|---|---|---|---|
| Gender | male | 96 | 87,0% | |
| female | 14 | 13,0% | ||
| Age | 60 (SD 9,92) | |||
| T-stage | T1 | 23 | 20,9% | |
| T2 | 32 | 29,1% | ||
| T3 | 25 | 22,7% | ||
| T4 | 30 | 27,3% | ||
| N-stage | N0 | 71 | 64,5% | |
| N1 | 11 | 10,0% | ||
| N2a | 0 | |||
| N2b | 13 | 11,8% | ||
| N2c | 14 | 12,7% | ||
| N3 | 1 | 1,0% | ||
| N0 vs. N+ | N0 | 71 | 64,5% | |
| N+ | 39 | 35,5% | ||
| M-stage | M0 | 108 | 98,2% | |
| M1 | 2 | 1,8% | ||
| Histopathological Grading | G1 | 6 | 5,5% | |
| G2 | 80 | 72,7% | ||
| G3 | 21 | 19,1% | ||
| unknown | 3 | 2,7% | ||
| Extracapsular lymph node spread | ECE | 3 | 7,7% | |
| No ECE | 29 | 74,4% | ||
| unknown | 7 | 17,9% | ||
| Therapy | surgery | 49 | 44,5% | |
| surgery + adjuvant RTX | 42 | 38,1% | ||
| surgery + adjuvant RCTX | 16 | 14,4% | ||
| RCTX | 1 | 1,0% | ||
| RTX | 1 | 1,0% | ||
| RCTX + salvage surgery | 1 | 1,0% | ||
ECE = extracapsular extension, RTX = radiotherapy, RCTX = radiochemotherapy.